VRTX : Summary for Vertex Pharmaceuticals Incorpor - Yahoo Finance

U.S. Markets open in 53 mins.

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
90.80+0.82 (+0.91%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close89.98
Bid89.20 x 100
Ask92.46 x 100
Day's Range88.90 - 91.49
52 Week Range71.46 - 103.73
Avg. Volume1,616,572
Market Cap22.56B
PE Ratio (TTM)-197.39
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com2 days ago

    Why Concert Pharmaceuticals Is Music to Investors' Ears

    This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.

  • American City Business Journals4 days ago

    Concert rebuffed $250M buyout offer from Vertex before CF drug deal

    Lexington-based Concert Pharmaceuticals rebuffed a $250 million buyout offer from Vertex Pharmaceuticals in November before ultimately striking a deal earlier this month to sell a cystic fibrosis drug to the Boston company for $160 million, according to a federal filing. Under the agreement, Vertex is slated to acquire the 69-employee biotech’s cystic fibrosis drug, CTP-656, a reformulation of Vertex’s approved treatment Kalydeco.

  • American City Business Journals11 days ago

    Inside the small Norwood biotech that's making investors swoon

    The top-performing public biotech in Massachusetts over the past year is located in a nondescript brick building with no signage, located along a stretch of highway in Norwood that is better known for its car dealerships than drug developers. Investors in Corbus Pharmaceuticals (CRBP) don’t much seem to mind. The company believes that its anti-inflammatory treatment — initially under the generic name of "resunab" but recently renamed "anabasum" — could treat several rare disorders.